The FDA has updated labeling for Kybella (deoxycholic acid) to warn clinicians of persistent nodules, masses, and adverse events linked to off-label use.

Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 trials show barzolvolimab significantly improves UAS7 and complete response rates in antihistamine-refractory CSU.

Out of all of the hematological parameters examined, only neutrophil-to-monocyte ratio was associated with ocular involvement in rosacea.

Pediatric patients with moderate to severe AD may have a reduced mean height and increased mean weight when compared with the general population.

Significant imbalances in sex hormones and oxidative stress were seen among women with severe acne vulgaris when compared with healthy controls.

Research is needed on the real-world performance of clinical AI tools in dermatology, yet many patients use available consumer-facing tools.

Nearly two-thirds of suspected poisonings in children can be handled by a call to a poison control center and do not require an ED visit.

The FDA has accepted an NDA with Priority Review for oral dersimelagon to treat erythropoietic protoporphyria and X-linked protoporphyria.

All participating US comprehensive cancer centers are experiencing a shortage of at least one anticancer agent.

Aminolevulinic acid hydrochloride in combination with photodynamic therapy has been approved for the treatment of BCC.

A dairy-free frozen dessert has been recalled for the second time in 9 months because its cashew pieces may contain small stones.

Results of a systematic review and meta-analysis confirm the efficacy and safety of oral JAK inhibitors for the treatment of alopecia areata.